Skip to main content
Year archive

Ascelia Pharma — 2025 filings

All 45 regulatory filings released by Ascelia Pharma (ACE) in 2025, sourced directly from the official regulator.

45 Filings
2025 Period
2025 filings (45)
Filing Released Lang
Valberedning utsedd i Ascelia Pharma AB inför årsstämman 2026
Regulatory Filings
2025-12-22 Swedish
Nomination Committee Appointed for AGM 2026 in Ascelia Pharma AB
AGM Information
2025-12-22 English
Ändring av antalet aktier och röster i Ascelia Pharma AB
Share Issue/Capital Change
2025-11-28 Swedish
Change in Number of Shares and Votes in Ascelia Pharma AB
Share Issue/Capital Change
2025-11-28 English
Ascelia Pharma beslutar om omvandling av C-aktier till stamaktier för leverans till deltagare i incitamentsprogram
Share Issue/Capital Change
2025-11-19 Swedish
Ascelia Pharma Resolves on Conversion of Series C Shares into Ordinary Shares for Delivery to Participants in Incentive Program
Share Issue/Capital Change
2025-11-19 English
Interim / Quarterly Report 2025
Interim / Quarterly Report 9M 2025
2025-11-05 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Q3 2025
2025-11-05 English
Ascelia Pharma Announces Management Changes to Support Future Growth
Board/Management Information
2025-11-03 English
Ascelia Pharma meddelar förändringar i ledningen för att stödja framtida tillväxt
Board/Management Information
2025-11-03 Swedish
Major Shareholding Notification 2025
Major Shareholding Notification
2025-10-23 Swedish
Ändring av antalet aktier och röster i Ascelia Pharma AB
Share Issue/Capital Change
2025-09-30 Swedish
Change in Number of Shares and Votes in Ascelia Pharma AB
Share Issue/Capital Change
2025-09-30 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-09-24 Swedish
Ascelia Pharma har genomfört en riktad nyemission om cirka 30 MSEK
Share Issue/Capital Change
2025-09-22 Swedish
Ascelia Pharma Has Completed a Directed Share Issue of Approximately SEK 30 Million
Share Issue/Capital Change
2025-09-22 English
Ascelia Pharma avser att genomföra en riktad nyemission av aktier om cirka 30 MSEK
Share Issue/Capital Change
2025-09-22 Swedish
Ascelia Pharma Intends to Carry Out a Directed Share Issue of Approximately SEK 30 Million
Capital/Financing Update
2025-09-22 English
Fenja Capital II A/S påkallar konvertering av samtliga utestående konvertibler med ett totalt nominellt belopp om 7,5 MSEK
Share Issue/Capital Change
2025-09-02 Swedish
Fenja Capital II A/S Requests Conversion of All Outstanding Convertibles for a Total Nominal Amount of SEK 7.5 Million
Share Issue/Capital Change
2025-09-02 English
Interim / Quarterly Report 2025
Interim / Quarterly Report H1 2025
2025-08-21 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report H1 2025
2025-08-21 English
Interim / Quarterly Report 2025
Interim / Quarterly Report Q1 2025
2025-05-16 Swedish
Investor Presentation 2025
Investor Presentation
2025-05-16 English
Kommuniké från årsstämma den 7 maj 2025 i Ascelia Pharma AB
AGM Information
2025-05-07 Swedish
Bulletin from the Annual General Meeting in Ascelia Pharma AB on 7 May 2025
AGM Information
2025-05-07 English
Change in Number of Shares and Votes in Ascelia Pharma AB
Declaration of Voting Results & Voting Rights Announcements
2025-04-30 English
Ändring av antalet aktier och röster i Ascelia Pharma AB
Declaration of Voting Results & Voting Rights Announcements
2025-04-30 Swedish
Ascelia Pharma Receives Gross Proceeds of SEK 43 Million from Exercise of Warrants Series TO 1
Capital/Financing Update
2025-04-16 English
Ascelia Pharma erhåller bruttolikvid om 43 MSEK från utnyttjande av teckningsoptioner serie TO 1
Share Issue/Capital Change
2025-04-16 Swedish
Annual Report (ESEF) 2024
Annual Report (ESEF) FY 2024
2025-04-11 Swedish
Kallelse till årsstämma i Ascelia Pharma AB
Proxy Solicitation & Information Statement
2025-04-04 Swedish
Notice of Annual General Meeting in Ascelia Pharma AB
Proxy Solicitation & Information Statement
2025-04-04 English
The Subscription Price for Warrants Series TO 1 in Ascelia Pharma has been Determined to SEK 2.15 and the Exercise Period is Initiated on 1 April 2025
Capital/Financing Update
2025-03-31 English
Teckningskursen för teckningsoptioner serie TO 1 i Ascelia Pharma har fastställts till 2,15 SEK och nyttjandeperioden inleds den 1 april 2025
Share Issue/Capital Change
2025-03-31 Swedish
Ascelia Pharma meddelar positivt utfall från FDA-möte och bekräftar planen att insända ansökan om marknadsgodkännande (NDA) för Orviglance i mitten 2025
Legal Proceedings Report
2025-03-18 Swedish
Ascelia Pharma Announces Positive Outcomes of FDA Meeting and Confirms Plan to Submit the NDA for Orviglance mid-2025
Legal Proceedings Report
2025-03-18 English
Kommuniké från extra bolagsstämma den 25 februari 2025 i Ascelia Pharma AB
AGM Information
2025-02-25 Swedish
Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 25 February 2025
AGM Information
2025-02-25 English
Nomination Committee Appointed for AGM 2025 in Ascelia Pharma AB
Board/Management Information
2025-02-12 English
Valberedning utsedd i Ascelia Pharma AB inför årsstämman 2025
AGM Information
2025-02-12 Swedish
Earnings Release 2024
Earnings Release Q4 2024
2025-02-07 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Q4 2024
2025-02-07 English
KALLELSE TILL EXTRA BOLAGSSTÄMMA I ASCELIA PHARMA AB
AGM Information
2025-01-30 Swedish
NOTICE OF EXTRAORDINARY GENERAL MEETING IN ASCELIA PHARMA AB
Proxy Solicitation & Information Statement
2025-01-30 English